课题基金 / 基金详情

LORAZEPAM AND ALPRAZOLAM: PERFORMANCE EFFECTS IN ELDERLY

LORAZEPAM AND ALPRAZOLAM: PERFORMANCE EFFECTS IN ELDERLY
劳拉西泮和阿普唑仑:对老年人表现的影响
批准号:
3381639
负责人:
Nunzio Pomara
金额:
$18.61万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-09-30 至 1994-08-31

项目摘要

项目成果

Nunzio Pomara的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Because of their widespread use, the acute and chronic effects of benzodiazepines on human performance are of considerable practical significance. The effects on the elderly (aged 60 to 78 years) are of particular concern since these individuals may be more sensitive to some of the adverse central effects of benzodiazepines. Moreover, normal age-related decline in cognitive functions may accentuate the significance of drug-induced deficits. Our current NIMH-sponsored study has found that diazepam, a benzodiazepine with a long elimination half-life (t 1/2), produced profound memory and psychomotor impairment after acute administration, and significant next-day memory impairment following chronic bedtime administration in elderly subjects. Moreover, only partial tolerance developed to the acute adverse effects after chronic administration. While it is often assumed that chronic treatment with benzodiazepines with shorter elimination half-lives (which results in less drug accumulation) will, in general, be associated with a smaller number of adverse effects on performance, there are few systematic studies of the effects of these drugs on performance in the elderly. Additionally, there are even fewer studies which include the very elderly, a group which may be partially vulnerable to the adverse effects of benzodiazepines. The aim of the proposed study is to assess the acute and chronic effects on task performance of alprozolam and lorazepam, two commonly prescribed benzodiazepines with relatively short t 1/2s. More specifically, this study is designed to answer the following questions: 1. What are the acute and chronic effects of alprazolam and lorazepam on task performance in the elderly? Do the two drugs differ with respect to these effects? 2. Within the elderly group, is increasing age associated with increased adverse effects on task performance? 3. What is the relationship between the magnitude of drug-induced impairment and drug plasma concentration?
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Depression treatment and Aβ dynamics: A study of Alzheimer’s disease risk
Depression treatment and Aβ dynamics: A study of Alzheimer’s disease risk
Depression treatment and Aβ dynamics: A study of Alzheimer’s disease risk
Plasma and CSF Abeta peptides in late-onset major depression
海外基金